CRISPR Therapeutics Hits Day Low at $48.24 Amid Price Pressure

CRISPR Therapeutics AG experienced significant volatility on November 20, 2025, with the stock declining by 7.82% and reaching an intraday low of USD 48.24. This performance stands in contrast to the S&P 500, which saw a modest gain of 0.38% on the same day. Over the past week, CRISPR's stock has decreased by 5.56%, while its monthly performance reflects a more substantial drop of 28.72%.
The company's financial metrics indicate ongoing challenges, with a return on equity (ROE) of just 3.15%, suggesting limited profitability relative to shareholder funds. CRISPR has reported negative results for four consecutive quarters, with net sales for the first nine months of the year plummeting by 81.48% to USD 37.45 million. Additionally, the net profit for the same period was a loss of USD 285.6 million, marking an 85.88% decline.

With a market capitalization of USD 4,930 million, CRISPR Therapeutics operates within the pharmaceuticals and biotechnology sector, facing a challenging environment characterized by negative EBITDA and a low return on capital employed (ROCE) of -25.34%.